Surrozen IncNASDAQ:SRZN
- LAST PRICE9.3300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.7400/ 2
- Ask / Lots14.9200/ 2
- Open / Previous Close0.0000 / 9.3300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SRZN |
|---|---|---|
| 09:32 ET | 726 | 9.51 |
| 10:14 ET | 100 | 9.6836 |
| 10:28 ET | 680 | 9.96 |
| 10:30 ET | 100 | 9.72 |
| 10:32 ET | 100 | 9.64 |
| 10:35 ET | 1055 | 9.5 |
| 10:37 ET | 800 | 9.6794 |
| 10:39 ET | 1136 | 10 |
| 10:50 ET | 200 | 9.99 |
| 10:53 ET | 200 | 10.0506 |
| 11:00 ET | 100 | 10.01 |
| 11:04 ET | 1844 | 10 |
| 11:11 ET | 100 | 10.2 |
| 11:13 ET | 200 | 10.46 |
| 11:18 ET | 100 | 10.74 |
| 11:20 ET | 615 | 10.48 |
| 11:24 ET | 1077 | 10.25 |
| 11:36 ET | 600 | 10.44 |
| 12:45 ET | 100 | 10.21 |
| 12:56 ET | 400 | 10.29 |
| 12:57 ET | 100 | 10.22 |
| 01:03 ET | 100 | 10.7365 |
| 01:06 ET | 100 | 10.5 |
| 01:08 ET | 500 | 10.5145 |
| 01:10 ET | 700 | 10.35 |
| 01:30 ET | 300 | 10.2 |
| 01:35 ET | 300 | 10.25 |
| 01:37 ET | 2502 | 9.95 |
| 01:42 ET | 111 | 10 |
| 02:40 ET | 300 | 10.38 |
| 03:56 ET | 5802 | 9.8 |
| 03:59 ET | 355 | 9.33 |
Apr 3, 2024
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis, from 8:40AM ET on Wednesday Apr 03, 2024 by Dow Jones
8:40AM ET on Wednesday Apr 03, 2024 by Dow Jones
Apr 1, 2024
DJ Surrozen Shares Tumble 26% on Securities Purchase Agreement, from 11:12AM ET on Monday Apr 01, 2024 by Dow Jones
11:12AM ET on Monday Apr 01, 2024 by Dow Jones*DJ Surrozen Announces Up to $192.5M Private Placement of Securities Priced At-the-Market Under Nasdaq Rules, from 8:31AM ET on Monday Apr 01, 2024 by Dow Jones
8:31AM ET on Monday Apr 01, 2024 by Dow JonesSurrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043, from 8:30AM ET on Monday Apr 01, 2024 by Dow Jones
8:30AM ET on Monday Apr 01, 2024 by Dow JonesSurrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules, from 8:30AM ET on Monday Apr 01, 2024 by Dow Jones
8:30AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Surrozen Inc | 29.8M | -0.4x | --- |
Mink Therapeutics Inc | 30.2M | -1.3x | --- |
NRX Pharmaceuticals Inc | 28.9M | -1.0x | --- |
Forte Biosciences Inc | 28.4M | -0.7x | --- |
Protara Therapeutics Inc | 31.4M | -0.8x | --- |
Nymox Pharmaceutical Corp | 28.0M | -5.6x | --- |
Company Information
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.
Contact Information
- Headquarters
- 171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-475-2820
- Fax
- 302-655-5049
Executives
- Non-Executive Chairman of the Board, Independent Director
- David Woodhouse
- President, Chief Executive Officer, Director
- Craig Parker
- Chief Financial Officer, Chief Operating Officer, Company Secretary
- Charles Williams
- Chief Medical Officer
- Geertrui Vanhove
- Independent Director
- Anna Berkenblit
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-21.35 |
Book Value | $18.39 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
